Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Accelerated Modulated Fractionation (SIB-IMRT) for the Treatment of Locally Advanced Squamous Cell Carcinoma From Head and Neck District
NCT03001570Phase 2Unknown
- Sponsor
- European Institute of Oncology
- Start
- Jan 2014
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KL-140 in head and neck squamous cell carcinoma (HNSCC), sponsored by European Institute of Oncology. Primary endpoint: Number of patients who experienced acute toxicity with Grade 3 or Grade 4 adverse events. Status: unknown.
02
Drugs
KL-140
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03001570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03001570.